TheNote
Pivotal DREAMM-2 study demonst... Note
GooglePlay AppStore
GSK press releases

Pivotal DREAMM-2 study demonstrated a clinically meaningful overall response rate with belantamab mafodotin (GSK2857916) for patients with relapsed/refractory multiple myeloma

Today announced treatment with the investigational single-agent belantamab mafodotin.
https://www.gsk.com/en-gb/media/press-releases/pivotal-dreamm-2-study-demonstrated-a-clinically-meaningful-overall-response-rate-with-belantamab-mafodotin-gsk2857916-for-patients-with-relapsedrefractory-multiple-myeloma/ gsk.com
RSS Hunter RSS Hunter • Dec 16, 2019